Literature DB >> 16807287

Prevalence of serum antibodies to human papilloma virus in patients with genital ulcer disease in an urban population of Tanzania.

J Mbwana1, R Viscidi, E Lyamuya, F Mhalu, G Chalamilla, J-A Liljeqvist, T Lagergård.   

Abstract

BACKGROUND: The epidemiology of human papillomavirus (HPV) in Tanzania is largely unknown both in risk groups and in the general population.
OBJECTIVE: To determine the cumulative seroprevalence of selected HPV types in order to evaluate exposure to HPV in urban Tanzania.
METHOD: In a cross-sectional study, sera of 200 patients of both sexes with genital ulcer disease (GUD) and sera of 60 male blood donors and 60 pregnant women were tested for antibodies to the oncogenic HPV types 16, 18, 31, 33, 35, 51 and 52 using an ELISA based on virus-like particles (VLP).
RESULTS: The overall seroprevalence of HPV types for all patients with GUD was 83% and 77% for women and men, respectively. For pregnant women and male blood donors, the corresponding percentages were 55% and 15%, respectively. The most common HPV types were 16, 18 and 52. Infection with multiple types was more than 10 and 5 times more frequent than infection with a single type 16 in patients with GUD and in pregnant women, respectively. The seroprevalence to HPV types 16, 18, 51 and 52 was considerably higher in HIV-positive patients with GUD than in HIV-negative patients.
CONCLUSIONS: Infections with the oncogenic HPV types 16, 18 and 52 are common among patients with GUD and pregnant women in urban Tanzania, emphasising the need for control, treatment and implementation of appropriate HPV vaccine programmes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807287      PMCID: PMC2598594          DOI: 10.1136/sti.2006.021279

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  10 in total

1.  Seroprevalence of human papillomavirus type 16 in pregnant women.

Authors:  M E Hagensee; J Slavinsky; C M Gaffga; J Suros; P Kissinger; D H Martin
Journal:  Obstet Gynecol       Date:  1999-11       Impact factor: 7.661

2.  The impact of human immunodeficiency virus type 1 status on human papillomavirus (HPV) prevalence and HPV antibodies in serum and cervical secretions.

Authors:  D J Marais; E Vardas; G Ramjee; B Allan; P Kay; R C Rose; A L Williamson
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

3.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis.

Authors:  G M Clifford; S Gallus; R Herrero; N Muñoz; P J F Snijders; S Vaccarella; P T H Anh; C Ferreccio; N T Hieu; E Matos; M Molano; R Rajkumar; G Ronco; S de Sanjosé; H R Shin; S Sukvirach; J O Thomas; S Tunsakul; C J L M Meijer; S Franceschi
Journal:  Lancet       Date:  2005 Sep 17-23       Impact factor: 79.321

4.  Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer.

Authors:  Alba-Lucia Combita; Maria-Mercedes Bravo; Antoine Touzé; Oscar Orozco; Pierre Coursaget
Journal:  Int J Cancer       Date:  2002-02-20       Impact factor: 7.396

5.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

6.  Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States.

Authors:  Deborah L Thompson; John M Douglas; Mark Foster; Michael E Hagensee; Carolyn Diguiseppi; Anna E Barón; Jennifer E Cameron; Timothy C Spencer; Jonathan Zenilman; C Kevin Malotte; Gail Bolan; Mary L Kamb; Thomas A Peterman
Journal:  J Infect Dis       Date:  2004-09-23       Impact factor: 5.226

7.  Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.

Authors:  Raphael P Viscidi; Linda Ahdieh-Grant; Barbara Clayman; Kelly Fox; Leslie S Massad; Susan Cu-Uvin; Keerti V Shah; Kathryn M Anastos; Kathleen E Squires; Ann Duerr; Denise J Jamieson; Robert D Burk; Robert S Klein; Howard Minkoff; Joel Palefsky; Howard Strickler; Paula Schuman; Eva Piessens; Paolo Miotti
Journal:  J Infect Dis       Date:  2003-01-06       Impact factor: 5.226

8.  Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities.

Authors:  Hinda J Ahmed; Judica Mbwana; Eva Gunnarsson; Karin Ahlman; Chalamilla Guerino; Liselott A Svensson; Fred Mhalu; Teresa Lagergard
Journal:  Sex Transm Dis       Date:  2003-02       Impact factor: 2.830

9.  Distribution of human papillomavirus in a family planning population in nairobi, kenya.

Authors:  Hugo De Vuyst; Sophia Steyaert; Lieve Van Renterghem; Patricia Claeys; Lucy Muchiri; Susan Sitati; Stijn Vansteelandt; Wim Quint; Bernard Kleter; Eric Van Marck; Marleen Temmerman
Journal:  Sex Transm Dis       Date:  2003-02       Impact factor: 2.830

10.  Genital human papillomavirus genotypes in northwestern Tanzania.

Authors:  Philippe Mayaud; Helen A Weiss; Charles J N Lacey; Dilbinder K Gill; David C W Mabey
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

  10 in total
  1 in total

1.  Prevalence of Anogenital Warts in Men with HIV/AIDS and Associated Factors.

Authors:  Caio Cavassan de Camargo; Karen Ingrid Tasca; Monica Banwart Mendes; Hélio Amante Miot; Lenice do Rosário de Souza
Journal:  Open AIDS J       Date:  2014-09-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.